Guillain-Barré syndrome following zimeldine treatment.
Autor(es): Fagius J.; Osterman P. O.; Sidén A.; Wiholm B. E.
Resumo: Thirteen cases of the Guillain-Barré syndrome are reviewed, all occurring with a similar relationship to recent commencement of treatment with the antidepressive drug zimeldine. The risk of developing Guillain-Barré syndrome was increased about 25-fold among patients receiving zimeldine, as compared with the natural incidence of the disorder. The cases described provide strong evidence that Guillain-Barré syndrome may occur as a specific, probably immunologically mediated, complication of drug therapy.
Imprenta: Journal of Neurology, Neurosurgery, and Psychiatry, v. 48, n. 1, p. 65-69, 1985
Identificador do objeto digital: 10.1136/jnnp.48.1.65
Descritores: Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Public health
Data de publicação: 1985
